Search
Patexia Research
Case number 1:20-cv-00019

Boehringer Ingelheim Pharmaceuticals Inc. et al v. Mylan Pharmaceuticals Inc. et al > Documents

Date Field Doc. No.Description (Pages)
Jun 30, 2023 217 Other Document Joint Proposed Schedule filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Law, Sandra) (Entered: 06/30/2023) (6)
Apr 12, 2023 211 ORDER DENYING JOINT MOTION REQUESTING RESCHEDULING OF STATUS CONFERENCE ECF NO. 210 . Signed by Chief District Judge Thomas S Kleeh on 4/12/2023. (snc) (Entered: 04/12/2023) (1)
Apr 12, 2023 212 MOTION for Leave to Appear Pro Hac Vice for Ashley Ross by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Law, Sandra) (Entered: 04/12/2023) (Main Document) (2)
Apr 12, 2023 213 ORDER. The parties are ORDERED to submit, on or before June 30, 2023, a joint proposed schedule to govern the case moving forward or an advisement as to why a joint proposed schedule could not be submitted. Signed by Chief District Judge Thomas S Kleeh on 4/12/2023. (snc) (Entered: 04/12/2023) (1)
Apr 12, 2023 214 MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Chief District Judge Thomas S Kleeh: Status Conference held on 4/12/2023. (Court Reporter Rachel Kocher.) (jb) (Entered: 04/12/2023) (0)
Apr 12, 2023 215 Pro Hac Vice filing fee for Ashley Ross in the amount of $200.00 paid. Receipt Number WVNC003675. (jb) (Entered: 04/12/2023) (0)
Apr 12, 2023 216 ORDER granting 212 Motion for Leave to Appear Pro Hac Vice for Ashley Ross filed by Boehringer Ingelheim Corporation. Signed by Chief District Judge Thomas S Kleeh on 4/12/2023. (jb) NEF reg on 4/21/2023 (jb). (Entered: 04/12/2023) (1)
Apr 12, 2023 212 MOTION for Leave to Appear Pro Hac Vice for Ashley Ross by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Law, Sandra) (Entered: 04/12/2023) (Proposed Order) (1)
Apr 11, 2023 210 Joint MOTION REQUESTING RESCHEDULING OF STATUS CONFERENCE by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 04/11/2023) (Main Document) (3)
Apr 11, 2023 210 Joint MOTION REQUESTING RESCHEDULING OF STATUS CONFERENCE by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 04/11/2023) (Proposed Order) (1)
Jan 5, 2023 209 ORDER GRANTING 208 JOINT MOTION TO RESCHEDULE STATUS CONFERENCE. Status Conference set for 4/12/2023 01:30 PM before Chief District Judge Thomas S Kleeh. The status conference will be conducted via ZoomGov video conference with an option to participate telephonically. Signed by Chief District Judge Thomas S Kleeh on 1/5/2023. (dk) (Entered: 01/05/2023) (2)
Jan 4, 2023 208 Joint Motion Requesting Rescheduling of Status Conference filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Law, Sandra). Wrong Event Used. Modified to make pending motion on 1/5/2023. NEF regen (dk). (Entered: 01/04/2023) (Main Document) (2)
Jan 4, 2023 208 Joint Motion Requesting Rescheduling of Status Conference filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Law, Sandra). Wrong Event Used. Modified to make pending motion on 1/5/2023. NEF regen (dk). (Entered: 01/04/2023) (Proposed Order) (1)
Oct 14, 2022 207 ORDER SCHEDULING STATUS CONFERENCE BY VIDEOCONFERENCE for 1/9/2023 01:30 PM before Chief District Judge Thomas S Kleeh. The parties can access the status conference via ZoomGov video conferencing with an option to participate telephonically. Signed by Chief District Judge Thomas S Kleeh on 10/14/2022. (dk) (Main Document 207 replaced with corrected document on 10/14/2022. NEF regen) (dk). (Entered: 10/14/2022) (2)
Oct 11, 2022 206 ORDER GRANTING JOINT MOTION REQUESTING RESCHEDULING OF STATUS CONFERENCE (ECF. NO. 205 ). For good cause shown, the motion is GRANTED [ECF No. 205]. The status conference is GENERALLY CONTINUED and will be rescheduled by separate order. Signed by Chief District Judge Thomas S Kleeh on 10/11/2022. (dk) (Entered: 10/11/2022) (1)
Oct 10, 2022 205 Joint MOTION Requesting Rescheduling of Status Conference re 204 Order, Set/Reset Hearings by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 10/10/2022) (Main Document) (2)
Oct 10, 2022 205 Joint MOTION Requesting Rescheduling of Status Conference re 204 Order, Set/Reset Hearings by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 10/10/2022) (Proposed Order) (1)
Aug 17, 2022 204 ORDER. Status Conference, by Zoom videoconferencing, set for 10/12/2022 01:30 PM, in Judge Kleeh Chambers before Chief District Judge Thomas S Kleeh. Signed by Chief District Judge Thomas S Kleeh on 8/17/2022. (dk) (Entered: 08/17/2022) (1)
Aug 11, 2022 202 Joint MOTION Requesting Rescheduling of Status Conference re 201 Order Cancelling Deadline,, Set/Reset Hearings, by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 08/11/2022) (Main Document) (2)
Aug 11, 2022 203 ORDER GRANTING JOINT MOTION REQUESTING RESCHEDULING OF STATUS CONFERENCE (ECF. NO. 202 ). The status conference is GENERALLY CONTINUED and will be rescheduled by separate order. Signed by Chief District Judge Thomas S Kleeh on 8/11/2022. (dk) (Entered: 08/11/2022) (1)
Aug 11, 2022 202 Joint MOTION Requesting Rescheduling of Status Conference re 201 Order Cancelling Deadline,, Set/Reset Hearings, by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 08/11/2022) (Proposed Order) (1)
Aug 4, 2022 201 ORDER RESCHEDULING STATUS CONFERENCE: The status conference is RESCHEDULED to August 15, 2022, at 2:45 p.m. The parties can access the status conference via ZoomGov video conferencing with an option to participate telephonically. Signed by Chief District Judge Thomas S Kleeh on 8/4/22. (jss) (Entered: 08/04/2022) (2)
Jul 11, 2022 200 ORDER RESCHEDULING STATUS CONFERENCE for 8/18/2022 11:00 AM before Chief District Judge Thomas S Kleeh. The parties can access the status conference via ZoomGov video conferencing with an option to participate telephonically. Signed by Chief District Judge Thomas S Kleeh on 7/11/2022. (dk) (Entered: 07/11/2022) (2)
Jul 8, 2022 199 ORDER GRANTING JOINT MOTION REQUESTING RESCHEDULING OF STATUS CONFERENCE: The 198 Motion to Continue is GRANTED. The July 11, 2022 Status Conference is GENERALLY CONTINUED. Signed by Chief District Judge Thomas S Kleeh on 7/8/2022. (cnd) (Entered: 07/08/2022) (1)
Jul 7, 2022 198 Joint MOTION to Continue Requesting Rescheduling of Status Conference by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Law, Sandra) (Entered: 07/07/2022) (Main Document) (2)
Jul 7, 2022 198 Joint MOTION to Continue Requesting Rescheduling of Status Conference by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Law, Sandra) (Entered: 07/07/2022) (Proposed Order) (1)
May 9, 2022 196 ORDER SCHEDULING STATUS CONFERENCE BY VIDEOCONFERENCE for 7/11/2022 12:30 PM before Chief District Judge Thomas S Kleeh. The parties can access the status conference via ZoomGov video conferencing with an option to participate telephonically. Signed by Chief District Judge Thomas S Kleeh on 5/9/2022. (dk) (Entered: 05/09/2022) (2)
May 9, 2022 197 MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Chief District Judge Thomas S Kleeh. Status Conference held on 5/9/2022. (Court Reporter Rachel Kocher.) (wrr) (Entered: 05/09/2022) (0)
May 2, 2022 195 ORDER RESCHEDULING STATUS CONFERENCE BY VIDEOCONFERENCE for 5/9/2022 11:00 AM before Chief District Judge Thomas S Kleeh. The parties can access the status conference via ZoomGov video conferencing with an option to participate telephonically. Signed by Chief District Judge Thomas S Kleeh on 5/2/2022. (dk) (Entered: 05/02/2022) (2)
Apr 25, 2022 194 ORDER RESCHEDULING STATUS CONFERENCE BY VIDEOCONFERENCE for 5/5/2022 10:30 AM before Chief District Judge Thomas S Kleeh. Signed by Chief District Judge Thomas S Kleeh on 4/25/2022. (dk) (Entered: 04/25/2022) (2)
Apr 5, 2022 192 CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. for NOTICE OF DEPOSITION OF MICHAEL BRAUN. (Copland, Gordon) (Entered: 04/05/2022) (2)
Apr 5, 2022 193 CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. for NOTICE OF DEPOSITION OF EVA ULRIKE GRAEFE-MODY. (Copland, Gordon) (Entered: 04/05/2022) (2)
Feb 10, 2022 190 MOTION to Withdraw as Attorney of Mira Mulvaney by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/10/2022) (Main Document) (3)
Feb 10, 2022 191 ORDER granting 190 Motion to Withdraw as Attorney. Attorney Mira Atanassova Mulvaney terminated. Signed by District Judge Thomas S. Kleeh on 2/10/22. (jss) (Entered: 02/10/2022) (1)
Feb 10, 2022 190 MOTION to Withdraw as Attorney of Mira Mulvaney by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/10/2022) (Proposed Order) (1)
Feb 4, 2022 189 TRANSCRIPT of Proceedings held on January 24, 2022, before Judge Thomas S. Kleeh. Court Reporter/Transcriber Lisa A. Cook, RPR-RMR-CRR-FCRR, Telephone number 304-347-3198. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days. Redaction Request due 2/25/2022. Redacted Transcript Deadline set for 3/7/2022. Release of Transcript Restriction set for 5/5/2022. (kac) (Entered: 02/04/2022) (13)
Jan 24, 2022 187 MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before District Judge Thomas S. Kleeh: Status Conference held on 1/24/2022. (Court Reporter Lisa Cook.) (jmm) (Entered: 01/24/2022) (0)
Jan 24, 2022 188 ORDER SCHEDULING STATUS CONFERENCE BY VIDEOCONFERENCE for 4/28/2022 11:00 AM in Clarksburg District Judge Courtroom, 2nd Floor before District Judge Thomas S. Kleeh. Signed by District Judge Thomas S. Kleeh on 1/24/2022. (dk) (Entered: 01/24/2022) (2)
Nov 10, 2021 186 ORDER granting 181 Motion to Withdraw : Attorney Guylaine Hache terminated. Signed by District Judge Thomas S. Kleeh on 11/10/21. (jss) (Entered: 11/10/2021) (1)
Oct 27, 2021 185 ORDER GRANTING IN PART MOTION TO EXTEND DEADLINES AND SCHEDULING STATUS CONFERENCE BY VIDEOCONFERENCE: The Court GRANTS the motion to extend the Close of Fact Discovery deadline to January 14, 2022. The Court DENIES the adoption of the agreed schedule outlined in the motion, and, rather, CONTINUES all other deadlines pending in this matter. The Court SCHEDULES a status conference forJanuary 24, 2022, at 11:00 a.m. Signed by District Judge Thomas S. Kleeh on 10/27/21. (jss) (Entered: 10/27/2021) (2)
Oct 26, 2021 183 Pro Hac Vice Filing fee for Sam Kwon: $ 200.00, receipt number WVNC003390 (jss) (Entered: 10/26/2021) (0)
Oct 26, 2021 184 ORDER granting 180 Motion for Leave to Appear pro hac vice of Sam Kwon. Signed by District Judge Thomas S. Kleeh on 10/26/21. (jss) (Entered: 10/26/2021) (1)
Oct 22, 2021 182 MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before District Judge Thomas S. Kleeh: Status Conference held on 10/22/2021. (Court Reporter Jill Cutter.) (jmm) (Entered: 10/22/2021) (0)
Oct 21, 2021 180 MOTION for Leave to Appear Pro Hac Vice of Sam Kwon by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 10/21/2021) (Main Document) (2)
Oct 21, 2021 181 MOTION to Withdraw as Attorney for Guylaine Hache by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Copland, Gordon) (Entered: 10/21/2021) (Main Document) (3)
Oct 21, 2021 181 MOTION to Withdraw as Attorney for Guylaine Hache by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Copland, Gordon) (Entered: 10/21/2021) (Proposed Order) (1)
Oct 21, 2021 180 MOTION for Leave to Appear Pro Hac Vice of Sam Kwon by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 10/21/2021) (Proposed Order) (1)
Oct 20, 2021 179 ORDER RESCHEDULING STATUS CONFERENCE BY VIDEOCONFERENCE to 10/22/2021 11:30 AM in Judge Kleeh Chambers before District Judge Thomas S. Kleeh. Signed by District Judge Thomas S. Kleeh on 10/20/2021. (dk) (Entered: 10/20/2021) (2)
Sep 23, 2021 177 Joint MOTION Requesting Status Conference by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 09/23/2021) (Main Document) (2)
Sep 23, 2021 178 ORDER SCHEDULING STATUS CONFERENCE BY VIDEOCONFERENCE granting 177 Motion. Status Conference set for 10/21/2021 10:00 AM before District Judge Thomas S. Kleeh. Signed by District Judge Thomas S. Kleeh on 9/23/21. (mh) (Entered: 09/23/2021) (2)
Sep 23, 2021 177 Joint MOTION Requesting Status Conference by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 09/23/2021) (Proposed Order) (1)
Sep 15, 2021 175 MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Senior Judge Irene M. Keeley. Status Conference held on 9/15/2021. (Court Reporter Cindy Knecht) (dk) (Entered: 09/15/2021) (0)
Sep 15, 2021 176 ORDER TRANSFERRING CASE. Case reassigned to District Judge Thomas S. Kleeh for all further proceedings. Senior Jud. ge Irene M. Keeley no longer assigned to case Signed by Senior Judge Irene M. Keeley on 9/15/21. (mh) (Entered: 09/15/2021) (1)
Sep 14, 2021 172 TRANSCRIPT of status conference held on 8/16/2021, before Judge Keeley. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 10/5/2021. Redacted Transcript Deadline set for 10/15/2021. Release of Transcript Restriction set for 12/13/2021. (ck) (Entered: 09/14/2021) (12)
Sep 14, 2021 173 TRANSCRIPT PURCHASE ORDER by Boehringer Ingelheim Corporation for proceedings held on 8/16/2021 before Judge Keeley. (ck) (Entered: 09/14/2021) (2)
Sep 14, 2021 174 TRANSCRIPT PURCHASE ORDER by Mylan Inc. for proceedings held on 8/16/2021 before Judge Keeley. (ck) (Entered: 09/14/2021) (2)
Sep 9, 2021 171 ORDER SCHEDULING STATUS CONFERENCE: The Court SCHEDULES a status conference for Wednesday, September 15, 2021, at 1:00 P.M. Signed by Senior Judge Irene M. Keeley on 9/9/21. (jss) (Entered: 09/09/2021) (1)
Aug 16, 2021 170 MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Senior Judge Irene M. Keeley. Status Conference held on 8/16/2021. (Court Reporter Cindy Knecht) (dk) (Entered: 08/16/2021) (0)
Jul 27, 2021 169 ORDER SCHEDULING STATUS CONFERENCE for 8/16/2021 11:30 AM via zoom before Senior Judge Irene M. Keeley. Signed by Senior Judge Irene M. Keeley on 7/27/21. (mh) (Entered: 07/27/2021) (1)
Jul 23, 2021 166 Other Document Notice of Withdrawal of Plaintiffs' Motion to Seal filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Certificate of Service)(Companion, James) (Entered: 07/23/2021) (Main Document) (2)
Jul 23, 2021 167 Unopposed Motion to Extend Deadlines filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Companion, James) Modified on 7/23/2021 - corrected event type (jss). (Entered: 07/23/2021) (7)
Jul 23, 2021 168 ORDER DENYING AS MOOT MOTION FOR LEAVE TO FILE UNDER SEAL (DKT. NO. 161 ). Signed by Senior Judge Irene M. Keeley on 7/23/21. (mh) (Entered: 07/23/2021) (1)
Jul 23, 2021 166 Other Document Notice of Withdrawal of Plaintiffs' Motion to Seal filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Certificate of Service)(Companion, James) (Entered: 07/23/2021) (Attachment Certificate of Service) (2)
Jul 19, 2021 162 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re documents produced 07/16/2021 (Companion, James) (Entered: 07/19/2021) (2)
Jul 19, 2021 163 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Supplemental Response to Mylan's First Joint Set of Interrogatories to Plaintiffs (Nos. 1-8, 17) (Companion, James) (Entered: 07/19/2021) (2)
Jul 19, 2021 164 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Plaintiffs' Rule 26(a) Second Supplemental Initial Disclosure Statement (Companion, James) (Entered: 07/19/2021) (2)
Jul 19, 2021 165 ORDER DIRECTING PLAINTIFFS TO SUPPLEMENT MOTION FOR LEAVE TO FILE UNDER SEAL [DKT. NO. 161 . The Court DIRECTS Boehringer, by Monday, July 26,2021, to supplement their motion to seal with additional information and authority. Signed by Senior Judge Irene M. Keeley on 7/19/21. (jss) (Entered: 07/19/2021) (4)
Jul 8, 2021 157 MOTION for Leave to Appear Pro Hac Vice of Andrew Walter by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 07/08/2021) (Main Document) (2)
Jul 8, 2021 158 Pro Hac Vice Filing fee for Andrew Walter: $ 200.00, receipt number WVNC003227 (jss) (Entered: 07/08/2021) (0)
Jul 8, 2021 159 ORDER granting Andrew Walter's 157 Motion for Leave to Appear pro hac vice. Signed by Senior Judge Irene M. Keeley on 7/8/21. (jss) (Entered: 07/08/2021) (1)
Jul 8, 2021 160 MEMORANDUM OPINION AND ORDER ADOPTING PLAINTIFFS PROPOSED CLAIM CONSTRUCTION. Signed by Senior Judge Irene M. Keeley on 7/8/21. (jss) (Entered: 07/08/2021) (22)
Jul 8, 2021 157 MOTION for Leave to Appear Pro Hac Vice of Andrew Walter by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 07/08/2021) (Proposed Order) (1)
Jul 2, 2021 152 Proposed Consent Judgment Order re Aurobindo Pharma Ltd. by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Companion, James) (Entered: 07/02/2021) (4)
Jul 2, 2021 153 CONSENT JUDGMENT re Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. and Aurobindo Pharma, LTD.The Complaint in Civil Action No. 5:20-cv-23 and all remaining claims, counterclaims, or affirmative defenses as to Aurobindo, are DISMISSED WITHOUT PREJUDICE and without costs, disbursements, or attorney fees to any party. This Court retains jurisdiction to enforce or supervise performance under this Consent Judgment and any related agreement(s). Signed by Senior Judge Irene M. Keeley on 7/2/2021. (kac) (Entered: 07/02/2021) (4)
Jul 2, 2021 154 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re documents produced 7-2-2021 (Companion, James) (Entered: 07/02/2021) (2)
Jul 2, 2021 155 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of Santanu Chakraborty (Companion, James) (Entered: 07/02/2021) (2)
Jul 2, 2021 156 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of Beth Britton (Companion, James) (Entered: 07/02/2021) (2)
May 10, 2021 150 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re documents produced to Defendant Aurobindo 5/10/2021 (Companion, James) (Entered: 05/10/2021) (2)
May 10, 2021 151 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re documents produced to Defendant Mylan 5/10/2021 (Companion, James) (Entered: 05/10/2021) (2)
Apr 28, 2021 149 Corporate Disclosure Statement by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. identifying Corporate Parent Mylan Inc. for Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.; Corporate Parent Viatris Inc. for Mylan Inc... (O'Brien, William) (Entered: 04/28/2021) (3)
Apr 23, 2021 148 ORDER granting 147 Motion Stipulated Joint Motion to Extend Deadlines. Signed by Senior Judge Irene M. Keeley on 4/23/21. (jss) (Entered: 04/23/2021) (2)
Apr 21, 2021 147 Joint MOTION To Extend Deadlines re 137 Order on Motion for Miscellaneous Relief,, Scheduling Order by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 04/21/2021) (Main Document) (4)
Apr 21, 2021 147 Joint MOTION To Extend Deadlines re 137 Order on Motion for Miscellaneous Relief,, Scheduling Order by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 04/21/2021) (Proposed Order) (2)
Apr 20, 2021 146 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Plaintiffs' Responses and Objections to Defendants' Notice of Deposition Under Federal Rule of Civil Procedure 30(b)(6) (Companion, James) (Entered: 04/20/2021) (2)
Apr 15, 2021 144 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Plaintiffs' documents served on Aurobindo 4-15-2021 (Companion, James) (Entered: 04/15/2021) (2)
Apr 15, 2021 145 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Plaintiffs' documents served on Mylan defendants 4-15-2021 (Companion, James) (Entered: 04/15/2021) (2)
Apr 14, 2021 143 CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Documents produced on 4.13.21). (O'Brien, William) (Entered: 04/14/2021) (2)
Apr 12, 2021 140 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of Shane Shupe (Companion, James) (Entered: 04/12/2021) (2)
Apr 12, 2021 141 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of Katie Reed (Companion, James) (Entered: 04/12/2021) (2)
Apr 12, 2021 142 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of Santanu Chakraborty (Companion, James) (Entered: 04/12/2021) (2)
Mar 4, 2021 138 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re documents served on Aurobindo defendants on March 2, 2021 (Companion, James) (Entered: 03/04/2021) (2)
Mar 4, 2021 139 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re documents served on Mylan defendants on March 2, 2021 (Companion, James) (Entered: 03/04/2021) (2)
Mar 1, 2021 137 ORDER: Order granting 135 Joint Motion to Extend Deadlines. Discovery due by 4/23/2021. Dispositive Motions due by 8/27/2021. Signed by Senior Judge Irene M. Keeley on 3/1/21. (jss) (Entered: 03/01/2021) (2)
Feb 26, 2021 131 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Plaintiffs' Objections and Responses to Mylan's First Joint Set of Rule 36 Requests for Admission (Nos. 1-40) and Plaintiffs' Response to Mylan's First Joint Set of Interrogatories to Plaintiffs (Nos. 1-20) (Companion, James) (Entered: 02/26/2021) (2)
Feb 26, 2021 132 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Plaintiffs' Response to Aurobindo's First Set of Rule 36 Requests for Admission (Nos. 1-40) and Plaintiffs' Response to Aurobindo's First Set of Interrogatories to Plaintiffs (Nos. 1-15) (Companion, James) (Entered: 02/26/2021) (2)
Feb 26, 2021 133 CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Documents produced on 2.25.21). (O'Brien, William) (Entered: 02/26/2021) (2)
Feb 26, 2021 134 CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. of Aurobindo's Responses and Objections to Plaintiffs' Requests for Admission. (Pizzo, John) (Entered: 02/26/2021) (1)
Feb 26, 2021 135 Joint MOTION to Extend Deadline by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/26/2021) (Main Document) (4)
Feb 26, 2021 136 CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Objections and Responses to Plaintiffs' First Set of Requests for Admission (Nos. 1-40)). (O'Brien, William) (Entered: 02/26/2021) (2)
Feb 26, 2021 135 Joint MOTION to Extend Deadline by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/26/2021) (Proposed Order) (2)
Feb 19, 2021 130 CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. of Responses and Objections to Plaintiffs Rule 30(B)(6) Notice of Deposition of Aurobindo Pharma Ltd. (Pizzo, John) (Entered: 02/19/2021) (1)
Feb 16, 2021 129 CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Documents produced on 2.16.21). (O'Brien, William) (Entered: 02/16/2021) (2)
Feb 11, 2021 128 Pro Hac Vice Filing fee for Tasha Francis Gerasimow: $ 200.00, receipt number WVNC003114 (jss) (Entered: 02/11/2021) (0)
Feb 10, 2021 125 MOTION for Leave to Appear Pro Hac Vice of Tasha Gerasimow by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/10/2021) (Main Document) (2)
Feb 10, 2021 126 ORDER granting 125 Motion for Leave to Appear Pro Hac Vice re: Tasha Francis Gerasimow. Signed by Senior Judge Irene M. Keeley on 2/10/21. (njz) (Entered: 02/10/2021) (1)
Feb 10, 2021 127 MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Senior Judge Irene M. Keeley. Markman Hearing held on 2/10/2021. (Court Reporter Cindy Knecht) (dk) (Entered: 02/10/2021) (0)
Feb 10, 2021 125 MOTION for Leave to Appear Pro Hac Vice of Tasha Gerasimow by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/10/2021) (Proposed Order) (1)
Feb 3, 2021 118 CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. Notice of Dep. of Hakaru Fujita. (Copland, Gordon) (Entered: 02/03/2021) (2)
Feb 3, 2021 119 CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. Notice of Dep. of Kenjii Egusa. (Copland, Gordon) (Entered: 02/03/2021) (2)
Feb 3, 2021 120 CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. Notice of Dep. of Megumi Maruyama. (Copland, Gordon) (Entered: 02/03/2021) (2)
Feb 3, 2021 121 CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. Notice of Dep. of Taakiaki Nishioka. (Copland, Gordon) (Entered: 02/03/2021) (2)
Feb 3, 2021 122 CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. Notice of Dep. of Thomas Friedl. (Copland, Gordon) (Entered: 02/03/2021) (2)
Feb 3, 2021 123 CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. Notice of Dep. of Michael Braun. (Copland, Gordon) (Entered: 02/03/2021) (2)
Feb 3, 2021 124 CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. of Defendants' Notice of 30(b)(6) Deposition. (Pizzo, John) (Entered: 02/03/2021) (1)
Feb 2, 2021 114 CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. of Defendants' Notice of Deposition of Klaus Dugi. (Pizzo, John) (Entered: 02/02/2021) (1)
Feb 2, 2021 115 CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. of Defendants' Notice of Deposition of Eva Ulrike Graefe-Mody. (Pizzo, John) (Entered: 02/02/2021) (1)
Feb 2, 2021 116 CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. of Defendants' Notice of Deposition of Ruth Harper. (Pizzo, John) (Entered: 02/02/2021) (1)
Feb 2, 2021 117 CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. of Defendants' Notice of Deposition of Hans-Juergen Woerle. (Pizzo, John) (Entered: 02/02/2021) (1)
Feb 1, 2021 109 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of Robert Cunard (Companion, James) (Entered: 02/01/2021) (2)
Feb 1, 2021 110 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of Roopak Sawhney (Companion, James) (Entered: 02/01/2021) (2)
Feb 1, 2021 111 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of V. Naga Prasad (Companion, James) (Entered: 02/01/2021) (2)
Feb 1, 2021 112 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of Akhilesh Dixit (Companion, James) (Entered: 02/01/2021) (2)
Feb 1, 2021 113 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of Naresh Nagubandi (Companion, James) (Entered: 02/01/2021) (2)
Jan 28, 2021 108 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Plaintiffs' First Set of Requests for Admission to Aurobindo (Companion, James) (Entered: 01/28/2021) (2)
Jan 27, 2021 105 CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (First Joint Set of Rule 36 Requests for Admission (Nos. 1-40)). (O'Brien, William) (Entered: 01/27/2021) (2)
Jan 27, 2021 106 CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (First Joint Set of Interrogatories to Plaintiffs (Nos. 1-20)). (O'Brien, William) (Entered: 01/27/2021) (2)
Jan 27, 2021 107 CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. re 104 Certificate of Service (Amended). (Pizzo, John) (Entered: 01/27/2021) (1)
Jan 26, 2021 99 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of Defendant Aurobindo Pharma Ltd. (Companion, James) (Entered: 01/26/2021) (2)
Jan 26, 2021 100 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of Ashis Kumar Mehta (Companion, James) (Entered: 01/26/2021) (2)
Jan 26, 2021 101 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of Shane Shupe (Companion, James) (Entered: 01/26/2021) (1)
Jan 26, 2021 102 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of Mylan defendants (Companion, James) (Entered: 01/26/2021) (2)
Jan 26, 2021 103 CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. First Set of Rule 36 Requests for Admission (Nos. 1-40) to Plaintiffs. (Pizzo, John) (Entered: 01/26/2021) (1)
Jan 26, 2021 104 CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. First Set of Interrogatories (Nos. 1-25) to Plaintiffs. (Pizzo, John) (Entered: 01/26/2021) (1)
Jan 22, 2021 98 ORDER SCHEDULING CLAIM CONSTRUCTION HEARING: The Court SCHEDULES the claim construction hearing in these consolidated matters for February 10, 2021, at 10:00 a.m. by videoconference. Signed by Senior Judge Irene M. Keeley on 1/22/21. (jss) (Entered: 01/22/2021) (1)
Jan 21, 2021 93 Pro Hac Vice Filing fee for Guylaine Hache: $ 200.00, receipt number WVNC003104 (jss) (Entered: 01/21/2021) (0)
Jan 21, 2021 94 ORDER : Order granting 88 Pro Hac Vice Application of Guylaine Hache. Signed by Senior Judge Irene M. Keeley on 1/21/20. (jss) (Entered: 01/21/2021) (1)
Jan 21, 2021 95 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Plaintiffs' Response to Defendants' First Set of Common Requests for Documents and Things to Plaintiffs (Nos. 1-69) (Companion, James) (Entered: 01/21/2021) (2)
Jan 21, 2021 96 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re documents produced on Mylan Defendants on 1/20/2021 (Companion, James) (Entered: 01/21/2021) (2)
Jan 21, 2021 97 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re documents produced on Aurobindo on 1/20/2021 (Companion, James) (Entered: 01/21/2021) (2)
Jan 20, 2021 92 DISCOVERY CONFIDENTIALITY ORDER. Signed by Senior Judge Irene M. Keeley on 1/20/21. (jss) (Entered: 01/20/2021) (30)
Jan 19, 2021 90 Proposed Discovery Confidentiality Order by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Companion, James) (Entered: 01/19/2021) (30)
Jan 19, 2021 91 ORDER GRANTING JOINT MOTION TO RESCHEDULE CLAIM CONSTRUCTION HEARING [DKT. NO. 89 and continues the claim construction hearing to a date to be determined. Signed by Senior Judge Irene M. Keeley on 1/19/21. (jss) (Entered: 01/19/2021) (1)
Jan 18, 2021 89 Joint MOTION To Reschedule Claim Construction Hearing by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 01/18/2021) (Main Document) (3)
Jan 18, 2021 89 Joint MOTION To Reschedule Claim Construction Hearing by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 01/18/2021) (Proposed Order) (1)
Jan 15, 2021 88 MOTION for Leave to Appear Pro Hac Vice (Guylaine Hache) by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 01/15/2021) (Main Document) (3)
Jan 15, 2021 88 MOTION for Leave to Appear Pro Hac Vice (Guylaine Hache) by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 01/15/2021) (Proposed Order) (1)
Jan 12, 2021 87 ORDER granting 86 Motion for Extension of Time and the completion of document production is extended toand including Tuesday, January 19, 2021. Signed by Senior Judge Irene M. Keeley on 1/12/21. (jss) (Entered: 01/12/2021) (1)
Jan 11, 2021 86 MOTION for Extension of Time to File Joint Motion to Extend Deadline by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 01/11/2021) (Main Document) (3)
Jan 11, 2021 86 MOTION for Extension of Time to File Joint Motion to Extend Deadline by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 01/11/2021) (Proposed Order) (1)
Jan 8, 2021 82 CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. Objections and Responses to Plaintiff's First Set of Interrogatories (Pizzo, John) (Entered: 01/08/2021) (1)
Jan 8, 2021 83 CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. Objections and Responses to Plaintiffs' First Set of Requests for Production of Documents and Things (Pizzo, John) (Entered: 01/08/2021) (1)
Jan 8, 2021 84 CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Objections and Responses to Plaintiff's First Set of Interrogatories (Nos. 1-10)). (O'Brien, William) (Entered: 01/08/2021) (2)
Jan 8, 2021 85 CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Objections and Responses to Plaintiffs' First Set of Requests to Mylan for the Production of Documents and Things (Nos. 1-78)). (O'Brien, William) (Entered: 01/08/2021) (2)
Dec 21, 2020 81 CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Defendants' First Set of Common Requests for Documents and Things to Plaintiffs (Nos. 1-69)). (O'Brien, William) (Entered: 12/21/2020) (2)
Dec 16, 2020 79 Defendants' Responsive Claim Construction Brief Other Document filed by Aurobindo Pharma, LTD., Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Affidavit Declaration of Wendy M. Ward in Support of Defendants' Responsive Claim Construction Brief, # 2 Exhibit Exhibit 1 to Declaration, # 3 Exhibit Exhibit 2 to Declaration, # 4 Exhibit Exhibit 3 to Declaration, # 5 Exhibit Exhibit 4 to Declaration)(Pizzo, John) (Entered: 12/16/2020) (Main Document) (16)
Dec 16, 2020 80 Other Document PLAINTIFFS RESPONSIVE BRIEF ON CLAIM CONSTRUCTION filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Companion, James) (Entered: 12/16/2020) (13)
Dec 16, 2020 79 Defendants' Responsive Claim Construction Brief Other Document filed by Aurobindo Pharma, LTD., Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Affidavit Declaration of Wendy M. Ward in Support of Defendants' Responsive Claim Construction Brief, # 2 Exhibit Exhibit 1 to Declaration, # 3 Exhibit Exhibit 2 to Declaration, # 4 Exhibit Exhibit 3 to Declaration, # 5 Exhibit Exhibit 4 to Declaration)(Pizzo, John) (Entered: 12/16/2020) (Affidavit Declaration of Wendy M. Ward in Support of Defendants' Responsive) (2)
Dec 16, 2020 79 Defendants' Responsive Claim Construction Brief Other Document filed by Aurobindo Pharma, LTD., Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Affidavit Declaration of Wendy M. Ward in Support of Defendants' Responsive Claim Construction Brief, # 2 Exhibit Exhibit 1 to Declaration, # 3 Exhibit Exhibit 2 to Declaration, # 4 Exhibit Exhibit 3 to Declaration, # 5 Exhibit Exhibit 4 to Declaration)(Pizzo, John) (Entered: 12/16/2020) (Exhibit Exhibit 1 to Declaration) (30)
Dec 16, 2020 79 Defendants' Responsive Claim Construction Brief Other Document filed by Aurobindo Pharma, LTD., Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Affidavit Declaration of Wendy M. Ward in Support of Defendants' Responsive Claim Construction Brief, # 2 Exhibit Exhibit 1 to Declaration, # 3 Exhibit Exhibit 2 to Declaration, # 4 Exhibit Exhibit 3 to Declaration, # 5 Exhibit Exhibit 4 to Declaration)(Pizzo, John) (Entered: 12/16/2020) (Exhibit Exhibit 2 to Declaration) (11)
Dec 16, 2020 79 Defendants' Responsive Claim Construction Brief Other Document filed by Aurobindo Pharma, LTD., Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Affidavit Declaration of Wendy M. Ward in Support of Defendants' Responsive Claim Construction Brief, # 2 Exhibit Exhibit 1 to Declaration, # 3 Exhibit Exhibit 2 to Declaration, # 4 Exhibit Exhibit 3 to Declaration, # 5 Exhibit Exhibit 4 to Declaration)(Pizzo, John) (Entered: 12/16/2020) (Exhibit Exhibit 3 to Declaration) (11)
Dec 16, 2020 79 Defendants' Responsive Claim Construction Brief Other Document filed by Aurobindo Pharma, LTD., Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Affidavit Declaration of Wendy M. Ward in Support of Defendants' Responsive Claim Construction Brief, # 2 Exhibit Exhibit 1 to Declaration, # 3 Exhibit Exhibit 2 to Declaration, # 4 Exhibit Exhibit 3 to Declaration, # 5 Exhibit Exhibit 4 to Declaration)(Pizzo, John) (Entered: 12/16/2020) (Exhibit Exhibit 4 to Declaration) (11)
Dec 11, 2020 78 ORDER: ORDERED that the deadline for the completion of document production is extended to and including Monday, January 11, 2021. Signed by Senior Judge Irene M. Keeley on 12/11/20. (jss) (Entered: 12/11/2020) (1)
Dec 10, 2020 77 Joint MOTION To Extend Deadline by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 12/10/2020) (Main Document) (3)
Dec 10, 2020 77 Joint MOTION To Extend Deadline by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 12/10/2020) (Proposed Order) (1)
Nov 25, 2020 75 Joint MOTION for Extension of Time to Complete Discovery to extend deadline for substantial completion of document production by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order Text of Proposed Order)(Law, Sandra) (Entered: 11/25/2020) (Main Document) (3)
Nov 25, 2020 76 ORDER: ORDERED that the deadline for the completion of document production is extended to and including Friday, December 11, 2020. Signed by Senior Judge Irene M. Keeley on 11/25/20. (jss) (Entered: 11/25/2020) (1)
Nov 25, 2020 75 Joint MOTION for Extension of Time to Complete Discovery to extend deadline for substantial completion of document production by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order Text of Proposed Order)(Law, Sandra) (Entered: 11/25/2020) (Proposed Order Text of Proposed Order) (1)
Nov 16, 2020 72 Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Main Document) (23)
Nov 16, 2020 73 Defendants' Opening Claim Construction Brief Other Document filed by Aurobindo Pharma, LTD.. (Pizzo, John) (Entered: 11/16/2020) (11)
Nov 16, 2020 74 Joint Defendants' Opening Claim [Corrected]Construction Brief Other Document filed by Aurobindo Pharma, LTD.. (Pizzo, John) (Entered: 11/16/2020) (12)
Nov 16, 2020 72 Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Attachment Declaration of Attorney James F. Companion) (3)
Nov 16, 2020 72 Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 1) (30)
Nov 16, 2020 72 Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 2) (5)
Nov 16, 2020 72 Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 3) (8)
Nov 16, 2020 72 Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 4) (14)
Nov 16, 2020 72 Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 5) (30)
Nov 16, 2020 72 Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 6) (30)
Nov 16, 2020 72 Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 7) (22)
Nov 16, 2020 72 Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 8) (30)
Nov 16, 2020 72 Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 9) (30)
Nov 16, 2020 72 Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 10) (6)
Nov 16, 2020 72 Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 11) (14)
Nov 16, 2020 72 Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 12) (14)
Nov 16, 2020 72 Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 13) (5)
Nov 16, 2020 72 Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 14) (30)
Nov 16, 2020 72 Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 15) (21)
Nov 16, 2020 72 Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 16) (4)
Oct 21, 2020 71 Joint Claim Construction and Pre-Hearing Statement Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A)(Companion, James) (Entered: 10/21/2020) (Main Document) (4)
Oct 21, 2020 71 Joint Claim Construction and Pre-Hearing Statement Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A)(Companion, James) (Entered: 10/21/2020) (Exhibit A) (6)
Oct 15, 2020 70 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Plaintiffs' Disputed Terms and Proposed Constructions and Initial Identification of Intrinsic Evidence (Companion, James) (Entered: 10/15/2020) (2)
Oct 14, 2020 69 CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD., Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. Defendants' Proposed Claim Constructions and Preliminary Identification of Intrinsic Evidence. (Pizzo, John) (Entered: 10/14/2020) (1)
Oct 7, 2020 67 CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD., Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. Defendants' Identification of Proposed Terms for Claim Construction. (Pizzo, John) (Entered: 10/07/2020) (2)
Oct 7, 2020 68 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. for Plaintiffs' Identification of Terms for Construction. (Companion, James) (Entered: 10/07/2020) (2)
Oct 1, 2020 66 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. PLAINTIFFS RESPONSE TO DEFENDANTS INVALIDITY CONTENTIONS. (Companion, James) (Entered: 10/01/2020) (2)
Sep 30, 2020 64 CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. Defendant Aurobindo Pharma Ltd.s Preliminary Noninfringement Contentions for U.S. Patent No. 9,486,526. (Pizzo, John) (Entered: 09/30/2020) (1)
Sep 30, 2020 65 CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Preliminary Responses to Plaintiffs' Infringement Contentions). (O'Brien, William) (Entered: 09/30/2020) (2)
Aug 4, 2020 63 PLAINTIFFS' ANSWER to 48 Answer to Complaint,, Counterclaim, of Defendants by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc..(Companion, James) (Entered: 08/04/2020) (14)
Aug 3, 2020 60 CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD., Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Defendants' Initial Invalidity Contentions). (O'Brien, William) (Entered: 08/03/2020) (2)
Aug 3, 2020 61 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. Plaintiffs' Contentions Against Mylan. (Companion, James) (Entered: 08/03/2020) (2)
Aug 3, 2020 62 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. Plaintiffs' Contentions Against Aurobindo. (Companion, James) (Entered: 08/03/2020) (2)
Jul 17, 2020 58 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Plaintiffs' Rule 26(a) Supplemental Initial Disclosure Statement (Companion, James) (Entered: 07/17/2020) (2)
Jul 17, 2020 59 CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Initial Disclosures Pursuant to Rule 26(a)(1)). (O'Brien, William) (Entered: 07/17/2020) (2)
Jul 14, 2020 57 Defendants' Answer to Plaintiffs' Complaint and Counterclaims in consolidated CAN 1:20CV90 ( Other Document ) filed by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 07/14/2020) (28)
Jul 10, 2020 56 CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. Aurobindo Defendants Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1). (Pizzo, John) (Entered: 07/10/2020) (2)
Jul 8, 2020 55 CONSENT ORDER OF CONSOLIDATION FOR ALL PURPOSESAND SCHEDULING ORDER: Initial Disclosures due by 7/17/2020. Dispositive Motions due by 8/10/2020. Claim Construction set for 1/20/2021 at 10:00 AM in Clarksburg District Judge Courtroom, 2nd Floor before Senior Judge Irene M. Keeley. Telephonic Status Conference set for 7/20/2021 at 01:00 PM before Senior Judge Irene M. Keeley. Proposed Pretrial Order due by 12/17/2021. Final Pretrial Conference set for 1/14/2022 at 10:00 AM in Clarksburg District Judge Courtroom, 2nd Floor before Senior Judge Irene M. Keeley. Bench Trial set for 1/24/2022 at 09:30 AM in Clarksburg District Judge Courtroom, 2nd Floor before Senior Judge Irene M. Keeley. (5 days) Signed by Senior Judge Irene M. Keeley on 7/8/20. (jss) (Entered: 07/08/2020) (5)
Jul 7, 2020 54 Proposed Consent Order of Consolidation for All Purposes and Scheduling Order by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Companion, James) (Entered: 07/07/2020) (5)
Jun 17, 2020 53 Plaintiffs' Answer to Defendant Aurobindo's Counterclaims Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Companion, James) (Entered: 06/17/2020) (7)
Jun 16, 2020 52 ORDER ADOPTING SCHEDULING ORDER. Signed by Senior Judge Irene M. Keeley on 6/16/20. (jss) (Entered: 06/16/2020) (1)
Jun 15, 2020 51 ORDER GRANTING MOTION TO CONSOLIDATE (filed in Civil Action No. 5:20-cv-23). Signed by District Judge John Preston Bailey on 6/15/2020. (copy to counsel via cm/ecf) (nmm) (Entered: 06/15/2020) (3)
Jun 2, 2020 50 ANSWER to 48 Answer to Complaint,, Counterclaim, by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc..(Companion, James) (Entered: 06/02/2020) (11)
May 13, 2020 49 Corporate Disclosure Statement by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. identifying Corporate Parent Mylan Inc., Corporate Parent Mylan N.V. for Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.; Corporate Parent Mylan N.V. for Mylan Inc... (O'Brien, William) (Entered: 05/13/2020) (3)
May 12, 2020 48 Mylan Defendants' ANSWER to 1 Complaint, and affirmative defenses and, COUNTERCLAIM for declaratory and other relief against Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. by Mylan Inc., Mylan Pharmaceuticals Inc., Mylan Laboratories Limited.(Copland, Gordon) (Entered: 05/12/2020) (22)
May 8, 2020 47 Document filed in wrong case. Document was filed in proper case 1:20cv90 and NEF regenerated (Main Document 47 replaced on 5/11/2020) (jss). Modified on 5/11/2020 (jss). (Entered: 05/08/2020) (1)
May 4, 2020 45 CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Plaintiffs Rule 26(a) Initial Disclosure Statement (Companion, James) (Entered: 05/04/2020) (1)
May 4, 2020 46 CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Defendants' Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1)). (O'Brien, William) (Entered: 05/04/2020) (2)
May 1, 2020 44 SCHEDULING ORDER: Claim construction hearing set for 1/20/2021 10:00 AM in Clarksburg District Judge Courtroom, 2nd Floor before Senior Judge Irene M. Keeley. Discovery due by 2/26/2021. Status Conference set for 7/20/2021 01:00 PM in Judge Keeley Chambers before Senior Judge Irene M. Keeley. Dispositive motions due by 8/10/2021. Proposed Pretrial Order due by 12/17/2021. Pretrial Conference/Final Settlement Conference set for 1/14/2022 10:00 AM in Clarksburg District Judge Courtroom, 2nd Floor before Senior Judge Irene M. Keeley. Bench Trial set for 1/24/2022 09:30 AM in Clarksburg District Judge Courtroom, 2nd Floor before Senior Judge Irene M. Keeley. Signed by Senior Judge Irene M. Keeley on 5/1/2020. (cnd) (Entered: 05/01/2020) (14)
Apr 27, 2020 43 MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Senior Judge Irene M. Keeley. Scheduling Conference held on 4/27/2020. (Court Reporter Stacy Harlow) (dk) (Entered: 04/27/2020) (0)
Apr 23, 2020 40 Pro Hac Vice Filing fees for B. Hales and J. Hurst: $ 400.00, receipt number WVNC002907 (jss) (Entered: 04/23/2020) (0)
Apr 23, 2020 41 ORDER granting Bryan S. Hales' 38 Motion for Leave to Appear pro hac vice. Signed by Senior Judge Irene M. Keeley on 4/23/20. (jss) (Entered: 04/23/2020) (1)
Apr 23, 2020 42 ORDER granting James F. Hurst's 36 37 Motion for Leave to Appear pro hac vice. Signed by Senior Judge Irene M. Keeley on 4/23/20. (jss) (Entered: 04/23/2020) (1)
Apr 21, 2020 39 REPORT of Rule 26(f) Planning Meeting. (Copland, Gordon) (Entered: 04/21/2020) (14)
Apr 20, 2020 37 MOTION to Amend/Correct 36 MOTION for Leave to Appear Pro Hac Vice of James F. Hurst by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 04/20/2020) (Main Document) (3)
Apr 20, 2020 38 MOTION for Leave to Appear Pro Hac Vice of Bryan S. Hales by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment, # 2 Proposed Order)(Companion, James) (Entered: 04/20/2020) (Main Document) (3)
Apr 20, 2020 37 MOTION to Amend/Correct 36 MOTION for Leave to Appear Pro Hac Vice of James F. Hurst by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 04/20/2020) (Proposed Order) (1)
Apr 20, 2020 38 MOTION for Leave to Appear Pro Hac Vice of Bryan S. Hales by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment, # 2 Proposed Order)(Companion, James) (Entered: 04/20/2020) (Attachment) (1)
Apr 20, 2020 38 MOTION for Leave to Appear Pro Hac Vice of Bryan S. Hales by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment, # 2 Proposed Order)(Companion, James) (Entered: 04/20/2020) (Proposed Order) (1)
Apr 16, 2020 36 MOTION for Leave to Appear Pro Hac Vice of James F. Hurst by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 04/16/2020) (Main Document) (3)
Apr 16, 2020 36 MOTION for Leave to Appear Pro Hac Vice of James F. Hurst by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 04/16/2020) (Proposed Order) (1)
Apr 10, 2020 34 Joint MOTION for Extension of Time to File Rule 26(f) Report by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 04/10/2020) (Main Document) (3)
Apr 10, 2020 35 ORDER: Order granting 34 Motion for Extension of Time to File and the Rule 26(f) planning reports are due on or before 4/20/20. Signed by Senior Judge Irene M. Keeley on 4/10/20. (jss) (Entered: 04/10/2020) (1)
Apr 10, 2020 34 Joint MOTION for Extension of Time to File Rule 26(f) Report by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 04/10/2020) (Proposed Order) (1)
Apr 9, 2020 33 STIPULATION REGARDING RESPONSIVE PLEADING DEADLINE (MAY12, 2020) by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 04/09/2020) (3)
Apr 2, 2020 31 MOTION to Withdraw of Atty. Leora Ben-Ami as counsel for Plaintiffs by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 04/02/2020) (Main Document) (2)
Apr 2, 2020 32 ORDER granting 31 Motion to Withdraw of Atty. Leora Ben-Ami as counsel for Plaintiffs. Signed by Senior Judge Irene M. Keeley on 4/2/20. (jss) (Entered: 04/02/2020) (1)
Apr 2, 2020 31 MOTION to Withdraw of Atty. Leora Ben-Ami as counsel for Plaintiffs by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 04/02/2020) (Proposed Order) (1)
Mar 4, 2020 27 ORDER granting Joseph M. Janusz's 26 Motion for Leave to Appear pro hac vice. Signed by Senior Judge Irene M. Keeley on 3/4/20. (jss) (Entered: 03/04/2020) (1)
Mar 4, 2020 28 ORDER granting Deepro R. Mukerjee's 25 Motion for Leave to Appear pro hac vice. Signed by Senior Judge Irene M. Keeley on 3/4/20. (jss) (Entered: 03/04/2020) (1)
Mar 4, 2020 29 ORDER granting Lance A. Soderstrom's 24 Motion for Leave to Appear pro hac vice. Signed by Senior Judge Irene M. Keeley on 3/4/20. (jss) (Entered: 03/04/2020) (1)
Mar 4, 2020 30 Pro Hac Vice Filing fees for D. Mukerjee, L. Soderstrom and J. Janusz: $ 600.00, receipt number WVNC002874 (jss) (Entered: 03/04/2020) (0)
Mar 3, 2020 24 MOTION for Leave to Appear Pro Hac Vice (Lance A. Soderstrom) by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 03/03/2020) (Main Document) (3)
Mar 3, 2020 25 MOTION for Leave to Appear Pro Hac Vice (Deepro R. Mukerjee) by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 03/03/2020) (Main Document) (3)
Mar 3, 2020 26 MOTION for Leave to Appear Pro Hac Vice (Joseph M. Janusz) by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 03/03/2020) (Main Document) (3)
Mar 3, 2020 25 MOTION for Leave to Appear Pro Hac Vice (Deepro R. Mukerjee) by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 03/03/2020) (Proposed Order) (1)
Mar 3, 2020 26 MOTION for Leave to Appear Pro Hac Vice (Joseph M. Janusz) by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 03/03/2020) (Proposed Order) (1)
Mar 3, 2020 24 MOTION for Leave to Appear Pro Hac Vice (Lance A. Soderstrom) by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 03/03/2020) (Proposed Order) (1)
Feb 28, 2020 22 WAIVER OF SERVICE Returned Executed by Mylan Laboratories Limited. Mylan Laboratories Limited waiver sent on 2/12/2020, answer due 4/13/2020. (O'Brien, William) (Entered: 02/28/2020) (1)
Feb 28, 2020 23 STIPULATION REGARDING RESPONSIVE PLEADING DEADLINE (APRIL 12, 2020) by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 02/28/2020) (3)
Feb 14, 2020 20 SUMMONS Returned Executed as to Mylan Pharmaceuticals Inc. service accepted by SOS on 2/6/2020. (jss) (Entered: 02/14/2020) (4)
Feb 14, 2020 21 SUMMONS Returned Executed as to Mylan Inc. service accepted by SOS on 2/6/2020. (jss) (Entered: 02/14/2020) (4)
Feb 13, 2020 11 MOTION for Leave to Appear Pro Hac Vice of Leora Ben-Ami by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/13/2020) (Main Document) (3)
Feb 13, 2020 12 MOTION for Leave to Appear Pro Hac Vice of Mira Mulvaney by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/13/2020) (Main Document) (3)
Feb 13, 2020 13 MOTION for Leave to Appear Pro Hac Vice of Jeanna Wacker by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/13/2020) (Main Document) (3)
Feb 13, 2020 14 MOTION to Withdraw as Counsel of Attorneys Thomas F. Fleming, Sam Kwon, Ashley Ross and Christopher J. Citro by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/13/2020) (Main Document) (2)
Feb 13, 2020 15 Pro Hac Vice fees for Leora Ben-Ami, Mira Mulvaney, and Jeanna Wacker: $ 600.00, receipt number WVNC002861. (cnd) (Entered: 02/13/2020) (0)
Feb 13, 2020 16 ORDER: It is ORDERED that the Court GRANTS Plaintiffs' 14 Motion for Leave to Withdraw as Counsel. Attorneys Sam Kwon, Ashley Ross, Christopher J. Citro and Thomas F. Fleming terminated. Signed by Senior Judge Irene M. Keeley on 2/13/2020. (cnd) (Entered: 02/13/2020) (1)
Feb 13, 2020 17 ORDER granting Leona Ben-Ami's 11 Motion for Leave to Appear pro hac vice. Signed by Senior Judge Irene M. Keeley on 2/13/20. (jss) (Entered: 02/13/2020) (1)
Feb 13, 2020 18 ORDER granting Mira Mulvaney's 12 Motion for Leave to Appear pro hac vice. Signed by Senior Judge Irene M. Keeley on 2/13/20. (jss) (Entered: 02/13/2020) (1)
Feb 13, 2020 19 ORDER granting Jeanna Wacker's 13 Motion for Leave to Appear pro hac vice. Signed by Senior Judge Irene M. Keeley on 2/13/20. (jss) (Entered: 02/13/2020) (1)
Feb 13, 2020 12 MOTION for Leave to Appear Pro Hac Vice of Mira Mulvaney by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/13/2020) (Proposed Order) (1)
Feb 13, 2020 13 MOTION for Leave to Appear Pro Hac Vice of Jeanna Wacker by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/13/2020) (Proposed Order) (1)
Feb 13, 2020 11 MOTION for Leave to Appear Pro Hac Vice of Leora Ben-Ami by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/13/2020) (Proposed Order) (1)
Feb 13, 2020 14 MOTION to Withdraw as Counsel of Attorneys Thomas F. Fleming, Sam Kwon, Ashley Ross and Christopher J. Citro by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/13/2020) (Proposed Order) (1)
Feb 12, 2020 10 ORDER -- FIRST ORDER AND NOTICE REGARDING DISCOVERY AND SCHEDULING: ***NOTICE TO ATTORNEYS*** : Pursuant to Rule 7.1 of the Federal Rules of Civil Procedure, ALL Non-governmental CORPORATE parties must file a DISCLOSURE STATEMENT with the Court. Forms are available on the Court's Web Site at http://www.wvnd.uscourts.gov/forms.htm Rule 26 Meeting to be held by 3/30/2020. Rule 26 Meeting Report due by 4/13/2020. Scheduling Conference set for 4/27/2020 at 01:00 PM in Judge Keeley Chambers before Senior Judge Irene M. Keeley. Discovery due by 5/4/2020. Signed by Senior Judge Irene M. Keeley on 2/12/20. (jss) (Entered: 02/12/2020) (3)
Feb 11, 2020 9 NOTICE of Appearance by William J O'Brien on behalf of Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (O'Brien, William) (Entered: 02/11/2020) (2)
Feb 5, 2020 1 Complaint* (1)
Feb 5, 2020 2 Supplemental Information for Patent Cases Involving an Abbreviated New Drug Application (ANDA) filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. (jss) (Entered: 02/05/2020) (2)
Feb 5, 2020 3 Corporate Disclosure Statement. (jss) (Entered: 02/05/2020) (2)
Feb 5, 2020 4 REPORT to USPTO on the filing or determination of an action regarding re 1 Complaint. (jss) (Entered: 02/05/2020) (1)
Feb 5, 2020 5 Filing fee: $ 400.00, receipt number WVNW002384 (jss) (Entered: 02/05/2020) (0)
Feb 5, 2020 8 VERIFICATION OF ATTORNEY ADMISSION as to L. Ben-Ami, T. Fleming, J. Wacker, M. Mulvaney, S. Kwon, A. Ross and C. Citro. (jss) (Entered: 02/05/2020) (1)
Menu